T2C2

Cytheris Announces Initiation of CONVERT, a Phase I/IIa Study of Recombinant Human Interleukin-7 (CYT107) in Combination with Antiviral Therapy and Vaccination for Treatment of Chronic Hepatitis B Virus

Targanta’s Oritavancin MAA accepted For Review By Emea Company Seeking Approval for the Treatment of Complicated Skin and Soft Tissue Infections in Europe

Aegera Therapeutics Collaboration With Human Genome Sciences Leads To The Initiation Of A Phase 1 Clinical Trial

The Leukemia & Lymphoma Society and Aegera Therapeutics Announce Collaboration to Open Clinical Trial

Lilly and TransPharma Medical Announce Licensing and Development Agreement

Targanta submits Marketing Authorization application for Oritavancin

Topigen Pharmaceuticals appoints Jeremy Curnock Cook to its Board of Directors

Human Genome Sciences initiates first clinical trial of lead IAP inhibitor HGS 1029 in advanced solid tumors

Cytochroma appoints R. Richard Wieland II as CFO

Topigen Pharmaceuticals to participate at upcoming medical conferences

Aegera Initiates Phase 1 Clinical Trial Of AEG33773 - A Small Molecule in Development for Diabetic Neuropathic Pain

Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients

Topigen Pharmaceuticals initiates European Phase 2 Clinical study of TPI ASM8 in patients with Asthma

Cytochroma initiates Phase I/II clinical trial of CTAP101 capsules for Vitamin D insufficiency in chronic kidney disease

Targanta Therapeutics announces Pricing of its Initial Public Offering

Aegera Therapeutics Initiates Four Phase I/II Clinical Trials for AEG35156

Cytheris Expands Interleukin-7 Clinical Development Program With International Phase I/IIa Trial In HIV

Topigen pharmaceuticals to advance TPI 1020 into phase 2 development for COPD

Enobia Pharma Raises $40.1 Million Series B Financing

Topigen secures C $26M (US $25M) in series C venture financing

Aegera Therapeutics Acquires Clinical Stage Oncology Company and Closes Concurrent Financing

Topigen to provide updates on novel treatments for respiratory diseases at conferences in Scotland and Canada.

Topigen to present updates on clinical programs at Biofinance 2007 and 2007 Bio International Convention.

Topigen expands executive team with senior business development and pharmaceutical development appointments.

Topigen and Novagali enter into strategic collaboration for allergic ocular diseases and allergic rhinitis.

TransPharma Medical named winner of 2007 red herring 100 Europe award.

TransPharma Medical expands board of directors with appointment of industry veteran Larry Ellberger.

Topigen initiates expanded phase II trial of inhaled TPI ASM8 in patients with asthma.

PainCeptor Pharma raises $24.4 M Series B Investment Round.

Cytochroma completes enrollment in phase II psoriasis trial.

Cytheris releases promising clinical data on its Interleukin-7 immune enhancer at the 2007 CROI meeting in Los Angeles.

Targanta announces $70 million series C financing.

Cytochroma Inc. announces completion of CDN$21 Million Financing Round.

Ambrilia announces that phase I study results support continued development of PPL-100, an investigational HIV/AIDS protease inhibitor.

Ambrilia announces further distribution partnerships for Europe for its lead oncology product, Octreotide.

Ambrilia announces European Licensing Partnership with Teva for its lead oncology product, octreotide.

Cytochroma initiates phase II clinical trial for psoriasis.

Study shows Ambrilia's PSP94 immunoassay to have prognostic value in prostate cancer management.

Ambrilia to present at the Rodman & Renshaw 8th annual healthcare conference in New-York.

Ambrilia announces positive results of a pivotal human pharmacokinetic study of its new prolonged release formulation of octreotide.

Cytheris announces the successful completion of its second financing round for EUR 24.3 (USD 30.7M).

Ambrilia announces share consolidation.

Ambrilia Biopharma and Merck sign licensing agreement granting Merck worldwide rights to Ambrilia's HIV/AIDS protease inhibitor program.

PainCeptor Pharma announces patent awards for its lead drug development programs.

Ambrilia to present at UBS Global Life Sciences Conference in New-York.

Topigen begins ind-enabling studies for TPI-1100 the first RNA-targeting compound to treat COPD.

Targanta appoints Mark Leuchtenberger as president and ceo.

Ambrilia appoints Mr. Luc Tanguay to its board of directors.

Ambrilia announces receipt of milestone payment from U.S. licensing partner for late-stage oncology specialty generic, Octreotide.

TransPharma Medical completes $18 Million Series C Financing.

Topigen reports positive therapeutic results from initial phase II trial studying inhaled TPI-ASM8 in patients with mild-to-moderate asthma.

Medicago announces positive results for MED-205: a product candidate for chronic treatment of high cholesterol.

BioAxone completes patient enrollment for phase I/IIa trial of Cethrin(R) in treatment of acute spinal cord injury.

Cytochroma acquires Proventiv Therapeutics to commercialize new Vitamin D products for CKD market.

Ambrilia highlights positive phase Ia results for its lead HIV protease inhibitor PPL-100 and latest developments in its product portfolio at annual meeting.

Ambrilia reports positive phase Ia results for its lead HIV/AIDS protease inhibitor PPL-100.

Cytochroma 's vitamin D analog shows promising results in multiple sclerosis model.

Cytheris : la thérapie par l'interkeukine. (french only)

Ambrilia reports issuance of U.S. Patent on PCK3145, its lead drug candidate for advanced metastatic prostate cancer.

Topigen initiates phase II program of TPI-1020 in respiratory disorders.

Cytochroma announces significant results with CTA002, a vitamin D analog and enzyme inhibitor, in a prostate cancer model.

Ambrilia announces board appointments.

CTA002, a novel vitamin D analog, shows significant anti-tumor activity in human neuroblastoma.

Topigen secures US$6.0M financing from MMV Financial Inc.

Dr. Mitchell Glass joins Topigen's scientific advisory board.

Transpharma-Medical to announce promising results of clinical trials with its hPTH (1-34)-Transdermal delivery product for osteoporosis treatment.

Chronogen secures (US) $3.275M of financing from MMV financial Inc.

Aegera Therapeutics Inc. today announced the publication of a scientific paper entitled "AEG3482".

Procyon announces receipt for short form prospectus.

Cytochroma granted FDA approval to commence phase II clinical trial for novel topical treatment of psoriasis.

Procyon to webcast special meeting of shareholders to approve merger via acquisition with Cellpep and $18.1 million financing.

Painceptor Pharma to accelerate ASICS pain therapeutics developement with NRC-IRAP contribution.

Topigen's CEO to present at Bio CEO & Investor Conference.

Procyon presents preclinical results with its novel tumor vasculature targeting drug, TVT-DOX, at the 2006 Miami Nature Biotechnology symposium on angiogenesis in cancer.

Targanta acquires late-stage antibiotic from Intermune.

Procyon and Cellpep to merge via acquisition creating a new global biopharmaceutical company: Ambrilia Biopharma Inc.

Procyon to receive $1 million in contribution from NRC-IRAP for its HIV/AIDS study.

Aegera receives approval from Health Canada to initiate a phase I clinical trial for AEG33783 - a drug designed to treat peripheral neuropathies.

Procyon' shares are now eligible within the Quebec SME growth stock plan.

Procyon receives regulatory approval to commence Phase I clinical trial for its lead HIV protease inhibitor, PPL-100.

Cethrin^(R) receives Orphan Drug Status. (english only)

Procyon to host conference call and webcast to explain PSP94 diagnostic marker study findings.

Study shows Procyon's PSP94 diagnostic marker is better at detecting aggressive prostate cancer.

Aegera's AEG35156 phase 1 oncology trial demonstrates target response in cancer patients.

Procyon reports new data for its lead HIV protease inhibitor, PPL-100, showing a potentially high genetic barrier against the HIV virus.

Procyon announces third quarter 2005 results.

PainCeptor achieves development milestones for innovative pain therapeutics program.

Aegera presentations at AACR-NCI-EORTC international conference on molecular targets and cancer therapeutic.

Topigen outlines strategy for respiratory disease product pipeline.

NicOx and Topigen sign agreement for NCX 1020 in COPD and other respiratory diseases .

Topigen initiates phase II clinical trial of lead drug candidate for asthma.

Procyon announces positive preclinical results for its lead HIV protease inhibitor, PPL-100.

Topigen adds to series B round an investment of CA$6 million from Caisse de dépôt et placement du Québec.

Positive results for UK clinical trial amendment for prostate cancer drug PCK3145.

Transpharma Medical announces Additions to Senior Management Team. Transpharma establishes US Operation.

Aegera initiates phase I combination oncology trial of XIAP antisense.

Laureate Pharma and Enobia Pharma Announce Development and Manufacturing Agreement on Therapeutic Enzyme Product.

Procyon's non-toxic therapeutic peptide targets prostate cancer in multiple ways to restrict disease development.

Topigen announces presentations at inaugural meeting of the oligonucleotide therapeutics society.

P rocyon announces second quarter 2005 financial results.

Cytochroma reports positive phase IB results for novel topical treatment of psoriasis.

Aegera appoints Dr. Jacques Jolivet as Vice President of Clinical Development.

Procyon presented its TVT-DOX new anti-cancer technology at the RSC/KAST 3^rd bilateral symposium: drug delivery systems.

Procyon completes the acquisition of Bioxalis Medica Inc. and closes a concurrent financing of $3.5 M.

Topigen introduces FANA^tm technology, new 3^rd generation chemistry for oligonucleotide-based therapeutics.

Procyon announced today that PCK3145 has shown a similar trend in MMP-9 level normalization in HRPC patients when they are treated with PCK3145 once weekly.